# Flux Power Holdings, Inc.: financial statements, quarterly

FLUX · Nasdaq · CIK 1083743 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/flux.md) · [Financials](/companies/flux/financials.md) · [Filings](/companies/flux/filings.md) · [Insiders](/companies/flux/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/flux/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.8](/filings/0001493152-25-011032.md) | [18.2](/filings/0001493152-25-011034.md) | [14.5](/filings/0001641172-25-009264.md) | [13.4](/filings/0001493152-25-004175.md) | [16.1](/filings/0001493152-25-022356.md) | [16.8](/filings/0001493152-26-006414.md) | [16.7](/filings/0001493152-26-021709.md) | [16.7 d](/filings/0001493152-26-039471.md) | [13.2](/filings/0001493152-25-022356.md) | [14.1](/filings/0001493152-26-006414.md) | [6.6](/filings/0001493152-26-021709.md) | [8.2 d](/filings/0001493152-26-039471.md) |
| Cost of revenue | $m | [10.6](/filings/0001493152-25-011032.md) | [12.8](/filings/0001493152-25-011034.md) | [10.4](/filings/0001641172-25-009264.md) | [9.8 d](/filings/0001493152-25-013771.md) | [10.9](/filings/0001493152-25-022356.md) | [11.4](/filings/0001493152-26-006414.md) | [11.5](/filings/0001493152-26-021709.md) | [11.0 d](/filings/0001493152-26-039471.md) | [9.4](/filings/0001493152-25-022356.md) | [9.2](/filings/0001493152-26-006414.md) | [4.8](/filings/0001493152-26-021709.md) | [6.0 d](/filings/0001493152-26-039471.md) |
| Gross profit | $m | [4.2](/filings/0001493152-25-011032.md) | [5.4](/filings/0001493152-25-011034.md) | [4.0](/filings/0001641172-25-009264.md) | [3.6](/filings/0001493152-25-004175.md) | [5.2](/filings/0001493152-25-022356.md) | [5.5](/filings/0001493152-26-006414.md) | [5.3](/filings/0001493152-26-021709.md) | [5.8 d](/filings/0001493152-26-039471.md) | [3.8](/filings/0001493152-25-022356.md) | [4.9](/filings/0001493152-26-006414.md) | [1.8](/filings/0001493152-26-021709.md) | [2.3 d](/filings/0001493152-26-039471.md) |
| Research and development | $m | [1.3](/filings/0001493152-25-011032.md) | [1.2](/filings/0001493152-25-011034.md) | [1.3](/filings/0001641172-25-009264.md) | [1.1 d](/filings/0001493152-25-013771.md) | [1.3](/filings/0001493152-25-022356.md) | [1.0](/filings/0001493152-26-006414.md) | [1.1](/filings/0001493152-26-021709.md) | [1.0 d](/filings/0001493152-26-039471.md) | [1.0](/filings/0001493152-25-022356.md) | [0.5](/filings/0001493152-26-006414.md) | [0.6](/filings/0001493152-26-021709.md) | [0.6 d](/filings/0001493152-26-039471.md) |
| Selling, general and administrative | $m | [4.7](/filings/0001493152-25-011032.md) | [4.6](/filings/0001493152-25-011034.md) | [5.3](/filings/0001641172-25-009264.md) | [4.3 d](/filings/0001493152-25-013771.md) | [5.1](/filings/0001493152-25-022356.md) | [6.0](/filings/0001493152-26-006414.md) | [5.7](/filings/0001493152-26-021709.md) | [5.5 d](/filings/0001493152-26-039471.md) | [4.9](/filings/0001493152-25-022356.md) | [3.6](/filings/0001493152-26-006414.md) | [4.2](/filings/0001493152-26-021709.md) | [3.7 d](/filings/0001493152-26-039471.md) |
| Operating income | $m | [(1.8)](/filings/0001493152-25-011032.md) | [(0.4)](/filings/0001493152-25-011034.md) | [(2.6)](/filings/0001641172-25-009264.md) | [(1.8)](/filings/0001493152-25-004175.md) | [(1.2)](/filings/0001493152-25-022356.md) | [(1.5)](/filings/0001493152-26-006414.md) | [(1.6)](/filings/0001493152-26-021709.md) | [(0.8) d](/filings/0001493152-26-039471.md) | [(2.2)](/filings/0001493152-25-022356.md) | [0.8](/filings/0001493152-26-006414.md) | [(3.0)](/filings/0001493152-26-021709.md) | [(2.1) d](/filings/0001493152-26-039471.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(2.2)](/filings/0001641172-25-009264.md) | [(0.9)](/filings/0001641172-25-009264.md) | [(3.0)](/filings/0001641172-25-009264.md) | [(2.2)](/filings/0001493152-25-004175.md) | [(1.7)](/filings/0001493152-26-021709.md) | [(1.9)](/filings/0001493152-26-021709.md) | [(1.9)](/filings/0001493152-26-021709.md) | [(1.2) d](/filings/0001493152-26-039471.md) | [(2.6)](/filings/0001493152-26-021709.md) | [0.6](/filings/0001493152-26-021709.md) | [(3.2)](/filings/0001493152-26-021709.md) | [(2.3) d](/filings/0001493152-26-039471.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001493152-25-011032.md) | [(0.06)](/filings/0001493152-25-011034.md) | [(0.18)](/filings/0001641172-25-009264.md) | [(0.13)](/filings/0001493152-25-004175.md) | [(0.10)](/filings/0001493152-25-022356.md) | [(0.11)](/filings/0001493152-26-006414.md) | [(0.12)](/filings/0001493152-26-021709.md) | not reported | [(0.15)](/filings/0001493152-25-022356.md) | [0.03](/filings/0001493152-26-006414.md) | [(0.15)](/filings/0001493152-26-021709.md) | not reported |
| Basic EPS | $ per share | [(0.13)](/filings/0001493152-25-011032.md) | [(0.06)](/filings/0001493152-25-011034.md) | [(0.18)](/filings/0001641172-25-009264.md) | [(0.13)](/filings/0001493152-25-004175.md) | [(0.10)](/filings/0001493152-25-022356.md) | [(0.11)](/filings/0001493152-26-006414.md) | [(0.12)](/filings/0001493152-26-021709.md) | not reported | [(0.15)](/filings/0001493152-25-022356.md) | [0.03](/filings/0001493152-26-006414.md) | [(0.15)](/filings/0001493152-26-021709.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | period not labelled (2025-01-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | period not labelled (2025-07-31) | period not labelled (2025-09-15) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.6](/filings/0001493152-25-013771.md) | [0.6](/filings/0001493152-25-011032.md) | [0.9](/filings/0001493152-25-011034.md) | [0.4](/filings/0001493152-25-011032.md) | [0.5](/filings/0001641172-25-009264.md) | [1.3](/filings/0001493152-26-039471.md) | [1.1](/filings/0001493152-25-013771.md) | [3.2](/filings/0001493152-26-039471.md) | [1.6](/filings/0001493152-25-022356.md) | [0.9](/filings/0001493152-26-006414.md) | [0.4](/filings/0001493152-26-021709.md) | [0.3](/filings/0001493152-26-039471.md) |
| Current assets | $m | [28.3](/filings/0001493152-25-013771.md) | [26.9](/filings/0001493152-25-011032.md) | [25.5](/filings/0001493152-25-011034.md) | not reported | [27.3](/filings/0001641172-25-009264.md) | [31.8](/filings/0001493152-26-039471.md) | not reported | not reported | [27.0](/filings/0001493152-25-022356.md) | [27.6](/filings/0001493152-26-006414.md) | [23.4](/filings/0001493152-26-021709.md) | [20.7](/filings/0001493152-26-039471.md) |
| Total assets | $m | [32.3](/filings/0001493152-25-013771.md) | [30.6](/filings/0001493152-25-011032.md) | [29.0](/filings/0001493152-25-011034.md) | not reported | [30.6](/filings/0001641172-25-009264.md) | [34.8](/filings/0001493152-26-039471.md) | not reported | not reported | [29.7](/filings/0001493152-25-022356.md) | [30.1](/filings/0001493152-26-006414.md) | [25.6](/filings/0001493152-26-021709.md) | [24.2](/filings/0001493152-26-039471.md) |
| Current liabilities | $m | [30.7](/filings/0001493152-25-013771.md) | [30.5](/filings/0001493152-25-011032.md) | [30.7](/filings/0001493152-25-011034.md) | not reported | [34.2](/filings/0001641172-25-009264.md) | [39.6](/filings/0001493152-26-039471.md) | not reported | not reported | [32.2](/filings/0001493152-25-022356.md) | [22.1](/filings/0001493152-26-006414.md) | [20.6](/filings/0001493152-26-021709.md) | [20.0](/filings/0001493152-26-039471.md) |
| Total liabilities | $m | [32.1](/filings/0001493152-25-013771.md) | [31.7](/filings/0001493152-25-011032.md) | [31.7](/filings/0001493152-25-011034.md) | not reported | [34.9](/filings/0001641172-25-009264.md) | [40.2](/filings/0001493152-26-039471.md) | not reported | not reported | [33.0](/filings/0001493152-25-022356.md) | [22.6](/filings/0001493152-26-006414.md) | [21.0](/filings/0001493152-26-021709.md) | [21.6](/filings/0001493152-26-039471.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [0.2](/filings/0001493152-26-039471.md) | [(1.1)](/filings/0001493152-26-021709.md) | [(2.7)](/filings/0001493152-26-021709.md) | not reported | [(4.4)](/filings/0001493152-26-021709.md) | [(5.4)](/filings/0001493152-26-039471.md) | not reported | not reported | [(3.3)](/filings/0001493152-26-021709.md) | [7.5](/filings/0001493152-26-021709.md) | [4.6](/filings/0001493152-26-021709.md) | [2.6](/filings/0001493152-26-039471.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,093)](/filings/0001493152-25-011032.md) | [(952) d](/filings/0001493152-25-011034.md) | [(229) d](/filings/0001641172-25-009264.md) | [(524) d](/filings/0001493152-25-013771.md) | [944](/filings/0001493152-25-022356.md) | [2,830 d](/filings/0001493152-26-006414.md) | [(1,566) d](/filings/0001493152-26-021709.md) | [(1,598) d](/filings/0001493152-26-039471.md) | [889](/filings/0001493152-25-022356.md) | [(5,163) d](/filings/0001493152-26-006414.md) | [(1,391) d](/filings/0001493152-26-021709.md) | [(253) d](/filings/0001493152-26-039471.md) |
| Capital expenditure | $k | [181](/filings/0001493152-25-011032.md) | [157 d](/filings/0001493152-25-011034.md) | [250 d](/filings/0001641172-25-009264.md) | [265 d](/filings/0001493152-25-013771.md) | [198](/filings/0001493152-25-022356.md) | [119 d](/filings/0001493152-26-006414.md) | [181 d](/filings/0001493152-26-021709.md) | [155 d](/filings/0001493152-26-039471.md) | [163](/filings/0001493152-25-022356.md) | [122 d](/filings/0001493152-26-006414.md) | [120 d](/filings/0001493152-26-021709.md) | [104 d](/filings/0001493152-26-039471.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | period not labelled (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.0](/filings/0001493152-25-004175.md) | [16.0](/filings/0001493152-25-004175.md) | [16.0](/filings/0001493152-25-004175.md) | [16.5](/filings/0001493152-25-011032.md) | [16.5](/filings/0001493152-25-011034.md) | [16.5](/filings/0001641172-25-009264.md) | [16.7](/filings/0001493152-25-022356.md) | [16.7](/filings/0001493152-26-006414.md) | [16.7](/filings/0001493152-26-021709.md) | [16.8](/filings/0001493152-25-022356.md) | [22.9](/filings/0001493152-26-006414.md) | [21.3](/filings/0001493152-26-021709.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,621,642 at 2026-08-14, from the cover of the [10-K filed 2026-08-20](/filings/0001493152-26-039471.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.